-
1.发明申请Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes 有权通过添加αGal表位增强肿瘤相关抗原的免疫原性公开(公告)号：US20090060930A1
公开(公告)日：2009-03-05
申请号：US11977203
申请日：2007-10-24
申请人： Mario R. Mautino , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
发明人： Mario R. Mautino , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
IPC分类号： A61K39/385 , C12P21/06 , C07K4/00 , C07K14/00 , C07C229/00 , C07H3/02 , C07H3/04 , C07H3/06
CPC分类号： C07H5/04 , A61K31/70 , A61K39/0011 , A61K39/39 , A61K2039/55511 , C07H15/00 , C07H15/04
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变以引入αGal表位或αGalglycomimetic表位，以便通过以下方式增强抗原的调理作用 天然抗αGal抗体刺激TAA捕获和表达，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
2.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US08551474B2
公开(公告)日：2013-10-08
申请号：US12890178
申请日：2010-09-24
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
3.发明授权Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes 有权通过添加αGal表位增强肿瘤相关抗原的免疫原性公开(公告)号：US07998486B2
公开(公告)日：2011-08-16
申请号：US11977203
申请日：2007-10-24
申请人： Mario R. Mautino , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
发明人： Mario R. Mautino , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
IPC分类号： A61K38/00
CPC分类号： C07H5/04 , A61K31/70 , A61K39/0011 , A61K39/39 , A61K2039/55511 , C07H15/00 , C07H15/04
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变以引入αGal表位或αGal糖模拟表位，以允许通过以下方式增强抗原的调理作用 天然抗αGal抗体刺激TAA捕获和表达，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
4.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 有权使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20110086067A1
公开(公告)日：2011-04-14
申请号：US12890178
申请日：2010-09-24
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，增强了抗原呈递细胞对调理肿瘤细胞的摄取，从而导致肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
5.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 审中-公开使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20070014775A1
公开(公告)日：2007-01-18
申请号：US11533199
申请日：2006-09-19
申请人： CHARLES LINK , TATIANA SEREGINA , GABRIELA ROSSI
发明人： CHARLES LINK , TATIANA SEREGINA , GABRIELA ROSSI
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
6.发明申请Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 审中-公开使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US20050201993A1
公开(公告)日：2005-09-15
申请号：US11013685
申请日：2004-12-16
申请人： Charles Link , Tatiana Seregina , Gabriela Rossi
发明人： Charles Link , Tatiana Seregina , Gabriela Rossi
IPC分类号： A01K67/027 , A61K39/00 , A61K48/00
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
7.发明授权Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes 有权通过添加αgal表位增强肿瘤相关抗原的免疫原性公开(公告)号：US08357777B2
公开(公告)日：2013-01-22
申请号：US13173692
申请日：2011-06-30
申请人： Mario R. Mautino , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
发明人： Mario R. Mautino , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
IPC分类号： A61K38/16
CPC分类号： C07H5/04 , A61K31/70 , A61K39/0011 , A61K39/39 , A61K2039/55511 , C07H15/00 , C07H15/04
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变以引入αGal表位或αGal糖模拟表位，以便允许增强抗原的调理作用 通过天然抗αGal抗体刺激TAA捕获和呈递，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
8.发明申请ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES 有权肿瘤相关抗体的增强免疫球蛋白增加ALPAGAL EPITOPES公开(公告)号：US20120003251A1
公开(公告)日：2012-01-05
申请号：US13173692
申请日：2011-06-30
申请人： Mario R. MAUTINO , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
发明人： Mario R. MAUTINO , Nicholas N. Vahanian , Won-Bin Young , Gabriela Rossi , Charles J. Link , Firoz Jaipuri
CPC分类号： C07H5/04 , A61K31/70 , A61K39/0011 , A61K39/39 , A61K2039/55511 , C07H15/00 , C07H15/04
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变以引入αGal表位或αGal糖模拟表位，以便允许增强抗原的调理作用 通过天然抗αGal抗体刺激TAA捕获和呈递，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
9.发明申请ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE 有权使用表达ALPHA（1,3） - 乳酸脱氢酶的ALLOGENEIC肿瘤细胞的抗肿瘤疫苗公开(公告)号：US20110250233A1
公开(公告)日：2011-10-13
申请号：US12878756
申请日：2010-09-09
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用增强了抗原呈递细胞对调理肿瘤细胞的摄取，这导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
10.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyl transferase 有权使用表达α（1,3） - 半乳糖基转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US07763461B2
公开(公告)日：2010-07-27
申请号：US11533184
申请日：2006-09-19
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用增强了抗原呈递细胞对调理肿瘤细胞的摄取，这导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.022 秒)
